Biotech entity
pharma is the sole category represented across all 1 tracked stories. Vyansa Intelligence is most often covered alongside Animal Regenerative Therapies, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Vyansa Intelligence is most often covered alongside Animal Regenerative Therapies, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The average consequence score is 6, matching the 6 beat baseline for this window. Vyansa Intelligence appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vyansa Intelligence. Shared-story counts are live from our verified record — not editorial picks.
The global animal regenerative therapies market is set for significant expansion, with a projected valuation of $870 million by 2032 according to Vyansa Intelligence. This growth is driven by a fundamental shift in veterinary medicine toward advanced biological solutions like stem cell therapy and platelet-rich plasma.
Vyansa Intelligence is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
